High-pressure impulse transient drug delivery for the treatment of proliferative diseases

• US 5,614,502 A
• Filed: 05/02/1994
• Issued: 03/25/1997
• Est. Priority Date: 01/15/1993
• Status: Expired due to Fees

• Current Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Anderson, Therese M., Flotte, Thomas J., McAuliffe, Daniel J., Doukas, Apostolos
• Primary Examiner(s): Kight, John
• Assistant Examiner(s): Lee, Howard C.
• Application Number:
  US08/236,265
• Time in Patent Office: 1,058 Days
• Field of Search: 204/157.62, 204/157.15, 514/410, 514/34, 540/145, 424/9.61, 607/2, 607/3, 607/61, 607/72
• US Class Current: 514/34
• CPC Class Codes: A61B 18/26 for producing a shock wave, e.g. laser lithotripsy
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/24 having an amino or nitro group
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 31/409 having four such rings, e.g. porphine derivatives, bilirubin, biliverdine hemin, hematin A61K31/555
• CPC Class Codes: A61N 7/00 Ultrasound therapy lithotripsy A61B17/22, A61B17/225; massage using supersonic vibration A61H23/00 ; using ultrasound for introducing media into the body A61M37/0092

Abstract

A method of treating diseases of cell proliferation in a patient such as neoplasms and rheumatoid arthritis including administering sub-toxic doses of a compound in combination with high pressure impulse transients. Methods are also provided for identifying compounds and impulse transient dosages useful for high pressure impulse transient chemotherapy.

Claims

1. A method of treating a patient with a disease characterized by the presence of a tumor, said method comprising:

administering to said patient a compound having a therapeutic index of at least 50, and

exposing a region of diseased tissue to at least one high-pressure compressional impulse transient when a level of said compound in surrounding healthy tissues is less than 50 percent of a level of said compound present in said region of diseased tissue, said exposing increasing permeability in cells comprised in said exposed region to facilitate localized delivery of said compound to said region of diseased tissue.

2. Method of claim 1, wherein said compound is a light activated dye compound.

3. Method of claim 1, wherein said disease is a solid neoplasm.

4. Method of claim 1, wherein administration of said impulse transients is during invasive surgery.

5. The method of claim 1, wherein said high pressure compressional impulse transient is generated by laser-induced plasma on a metallic surface.

6. The method of claim 1, wherein said high pressure compressional impulse transient is generated by laser-induced ablation.

7. The method of claim 1, wherein said high pressure compressional impulse transient is generated by rapid heating of an absorbing material.

8. The method of claim 7, wherein said rapid heating of said absorbing material is generated by a laser.

9. The method of claim 1, wherein said high pressure compressional impulse transient is generated by laser-induced plasma on a metallic surface.

10. The method of claim 1, wherein said high pressure compressional impulse transient is generated by laser-induced ablation.

11. The method of claim 1, wherein said high pressure compressional impulse transient is generated by rapid heating of an absorbing material.

12. The method of claim 11, wherein said rapid heating of said absorbing material is generated by a laser.

13. A method of treating a patient with a disease characterized by the presence of a tumor, said method comprising:

administering to said patient a compound selected from the group consisting of Photofrin II, Prodan, Rhodamine 123, tetrabrominated rhodamine, tetracycline and cisplatinum, and

exposing a region of diseased tissue to at least one high-pressure compressional impulse transient when a level of said compound in surrounding healthy tissue is less than 50 percent of a level of said compound present in said region of diseased tissue, said exposing increasing permeability in cells comprised in said exposed region to facilitate localized delivery of said compound to said region of diseased tissue.